Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IJ0F
|
|||
| Former ID |
DIB016941
|
|||
| Drug Name |
AG-013
|
|||
| Synonyms |
ActoBiotic (oral mucositis), ActoGenix; TFF-producing Lactococci lactis (mucositis), ActoGenix/VIB/University of Ghent; Trefoil factor producing micro-organisms (TopAct, oral, mucositis), ActoGenix
Click to Show/Hide
|
|||
| Indication | Oral mucositis [ICD-11: DA01.11; ICD-10: K12.3; ICD-9: 528] | Phase 2/3 | [1] | |
| Company |
Flanders Interuniversity Institute for Biotechnology (VIB)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Trefoil factor-1 (TFF1) | Target Info | Modulator | [1] |
| Panther Pathway | CCKR signaling map ST | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.